2.Study on the effect of Longdanxiegan capsule on serum sVCAM-1, immune globulin and SOD level in patients with sudden deafness and tinnitus
Zhaodong ZHANG ; Shun WU ; Zhaoyang ZHOU ; Jing SHAO ; Liyuan BAI ; Zhiyong WANG
Chinese Journal of Biochemical Pharmaceutics 2015;(12):117-119
Objective To analysis the effect of Longdanxiegan capsule on serum sVCAM-1, immune globulin and SOD level in patients with sudden deafness and tinnitus.Methods 48 patients who were diagnosed with sudden deafness and tinnitus were collected.All patients were randomly divided into experimental group and control group,24 cases in each group.Patients in the control group received conventional western medicine treatment, patients in the experimental group were given Erlongzuoci pill on the basis of control group treatment , after the treatment, the serum levels of sVCAM-1, IgG, IgA, IgM and SOD were detected in all patients.Results After treatment, compared with control group, the serum levels of sVCAM-1 was lower in the experimental group,and the difference was statistically significant(P<0.05);the serum IgG, IgA and IgM levels were lower in the experimental group (P<0.05); the serum SOD level was higher in the experimental group (P<0.05).Conclusion The Longdanxiegan capsule can reduce significantly the serum sVCAM-1, IgG, IgA and IgM levels, improve serum SOD level in patients with sudden deafness and tinnitus, improve immune function and the ability to remove free radicals , and have a guiding significance for clinica .
3.Clinical efficacy and prognostic factors of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma
Wenwen BAI ; Yuzhi SONG ; Yongzhi QIAO ; Liyuan FU ; Ruohui ZHANG ; Chanjun ZHEN ; Xueying QIAO
Chinese Journal of Radiation Oncology 2018;27(6):570-575
Objective To evaluate the clinical efficacy and analyze relevant prognostic factors of simultaneous integrated boost intensity-modulated radiation therapy ( SIB-IMRT ) for esophageal squamous cell carcinoma. Methods A total of 101 patients diagnosed with esophageal squamous cell carcinoma received SIB-IMRT from 2009 to 2015. The prescribed dose of PTV was 5040 cGy/28 times ( 180 cGy/time) and the dose for planning gross tumor volume (PGTV) was 6020 cGy/28 times (215 cGy/time) or 6160 cGy/28 times ( 220 cGy/time) simultaneously. The total treatment time was 5. 5 weeks ( once a day, 5 times a week).The adverse events, mode of treatment failure,l-,3-and 5-year local control (LC) and overall survival ( OS) rates were observed. Results The quantity of patients who completed the 1-,3-and 5-year follow-up was 101, 84 and 45, respectively. The 1-,3-and 5-year LC rates were 81. 6%,70. 4% and 68. 4%, respectively. The 1-, 3-and 5-year OS rates were 72. 3%, 49. 4% and 45. 2%, respectively. The median survival time was 36 months. Univariate and multivariate analyses showed that clinical staging ( stageⅠ/Ⅱ/Ⅲ) and tumor response ( complete remission/ partial remission/no remission ) were the prognostic factors of OS (P=0. 016,0. 000,0. 005,0. 000).There were no significant differences in the LC and OS between the two groups of 215 cGy and 220 cGy (P=0. 283,0. 951).The incidence rates of grade 1,2,3 acute pneumonitis were 10. 9%(11/101),2. 0%(2/101) and 2. 0%(2/101), respectively. The incidence rates of grade 1, 2, 3 acute esophagitis were 63. 4%( 64/101 ) , 10. 9%( 11/101 ) and 4. 0%( 4/101 ) , respectively. No acute esophageal perforation or hemorrhage occurred. Five patients experienced late pneumonitis ( two died) . One case developed late lemostenosis, two cases developed esophageal perforation and hemorrhage, and two patients experienced esophageal hemorrhage. The patients treated with a fractionated dose of 220 cGy had a higher incidence rate of acute pneumonitis and upper gastrointestinal adverse reactions than those receiving 215 cGy ( P= 0. 062, 0. 024 ) . The local failure and recurrence accounted for 62. 5% of all treatment-related failures. Conclusions SIB-IMRT yields high long-term clinical efficacy and tolerable adverse events in the treatment of esophageal squamous cell carcinoma. Compared with the dose of 215 cGy, the fractionated dose of 220 cGy fails to improve LC and OS rates, whereas enhances the risk of adverse events. The clinical staging and short-term clinical efficacy are the prognostic factors of survival rate.
4.Comparison of simultaneous integrated boost and late course boost intensity-modulated radiation therapy in the treatment of esophageal carcinoma
Wenwen BAI ; Liyuan FU ; Jing LI ; Ruohui ZHANG ; Chanjun ZHEN ; Rui ZHANG ; Shuoshuo WANG ; Ming LIU ; Xueying QIAO
Chinese Journal of Radiological Medicine and Protection 2018;38(4):258-264
Objective To analyze and compare the outcomes of esophageal carcinoma treated with simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) and late course boost intensity-modulated radiation therapy (LCB-IMRT).Methods We retrospectively analyzed 128 patients with esophageal squamous cell carcinoma who were treated with SIB-IMRT or LCB-IMRT at the fifth department of radiation oncology in our hospital,from January 2009 to August 2015.Propensity score matching analysis was used to balance the variables differences in the two groups.Survival,failure patterns and toxicities were observed and compared between the two groups.Results one hundred and eleven patients were finally included after propensity scores matching.The 1-,3-and 5-year local control rates and survival rates were 83.6% vs.81.7%,70.8% vs.46.3% and 66.0% vs.38.2% in the whole group,respectively.The 1-,3-and 5-year local control rates of SIB-IMRT and LCB-IMRT group were 81.6% vs.88.0%,72.3% vs.67.6% and68.5% vs.60.8%,respectively (P>0.05).The 1-,3-and 5-year survival rates of SIB-IMRT and LCB-IMRT group were 81.3% vs.82.4%,51.7% vs.36.7% and 45.8% vs.26.7%,respectively (P > 0.05).There was no statistical difference between the two group in ≥ grade 3 toxicities (P > 0.05).There were 40 (36.0%) patients result in treatment failure in all.The treatment failure rates in SIB-IMRT and LCB-IMRT group were 33.8% (26/77) vs.41.2% (14/34),respectively (P > 0.05).The local failure accounted for 65.0% (26/40) of all treatment-related failures.Conclusions The toxicities of esophageal squamous cell carcinoma treated with SIB-IMRT and LCB-IMRT have no significant differences and were well tolerated.There were no significant differences in local control rates and survival rates between the two groups.However,SIB-IMRT had better trend than LCB-IMRT.Given SIB-IMRT's convenient manipulation,it could be a better choice in the treatment of advanced esophageal carcinoma.
5.Inhibitory effects of allicin effective component DATS on Enterococcus faecalis bofilm:An in vitro Study
Liyuan WANG ; Simin SHEN ; Xijing BAI
Journal of Practical Stomatology 2024;40(1):104-108
Objective:To investigate the antibacterial efficacy of allicin effective component,dially trisulfide(DATS),on the biofilms of Enterococcus faecalis(E.faecalis)in vitro.Methods:60 healthy single root canal permanent teeth were selected.After cleaning and autoclaving,15 teeth without infection were used in the negative control group,45 teeth were contaminated by E.faecalis and incubated for 28 days as the infection models and devided into 3 groups(n=15)as below:DATS group,Calcium hydroxide group and positive(without antibacteria treatment)control group.The minial inhibition concentration(MIC)and minial bactericidal concentrition(MBC)of DATS on E.feacalis were studied with doubling diluting method.At the day 1,2 and 7 of the exprement,the 4 mg of root canal in-ner dentin powder,5 specimens of each group were sespectively transfered into sterile bottle containing 2 mL BHI broth and cultured at 37 ℃ 5%CO2 for 72 h,the turbitity of the upper layer of liquid of the culture was measured.Results:MIC and MBC(μg/mL)of DATS to E.feacalis was 2 560 and 5 120 repsectively.At the first day,turbidity in the DATS group was the lowest(P<0.05).At the third day,turbidity showed no difference between DATS group and negative control group(P=0.454).At the 7th day,between calcium hydroxide and the negative control group,P<0.05.Conclusion:DATS may suppress E.faecalis in the biofilm in vitro.
6.Detection of meningeal carcinomatosis by metagenomic next-generation sequencing and copy number variation analysis of cerebrospinal fluid
Haitao REN ; Shan LIU ; Kechi FANG ; Siyuan FAN ; Liyuan GUO ; Lin BAI ; Jing WANG ; Hongzhi GUAN
Chinese Journal of Neurology 2023;56(5):526-531
Objective:To evaluate the significance of copy number variation (CNV) and metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) in the diagnosis of meningeal carcinomatosis (MC).Methods:Ten patients with MC diagnosed in the Department of Neurology of Peking Union Medical College Hospital from March 2022 to June 2022 were consecutively enrolled in this study. The patients were diagnosed according to the criteria of the Chinese expert consensus on the diagnosis of MC by the Chinese Society of Infectious Diseases and Cerebrospinal Fluid Cytology, and the diagnosis of MC was confirmed by CSF cytology. The control group included 10 patients who were diagnosed as autoimmune encephalitis or viral encephalitis. CSF mNGS and CNV analysis were performed simultaneously in all the patients.Results:Of the 10 patients with MC, 6 had lung adenocarcinoma, 4 had breast cancer. CSF mNGS and CNV analysis detected large CNV in 8 of 10 patients with MC, including 4 patients with breast cancer and 4 patients with lung cancer. The results of pathogenic microorganism analysis of CSF mNGS in all the patients were negative. Meanwhile, large CNV was not detected in the control group.Conclusions:CSF CNV can serve as a diagnostic marker for MC. The combination of mNGS and CNV analysis has demonstrated a high positive rate in the diagnosis of MC. The dual-omics analysis of pathogenic microorganisms and CNV has been proposed as a potential strategy to further expand the clinical utility of CSF mNGS in the realm of auxiliary diagnosis.
7.Preliminary Analysis of Influencing Factors of Opioid Analgesics Need Within 48 Hours After Arthroscopic Rotator Cuff Repair
Yingying XU ; Yue BAI ; Shuo YANG ; Xiaowen LI ; Boxuan DONG ; Liyuan TAO ; Yuping YANG
Chinese Journal of Minimally Invasive Surgery 2023;23(12):898-901
Objective To investigate the influencing factors of opioid analgesics need within 48 hours after arthroscopic rotator cuff repair.Methods Clinical data of 90 consecutive arthroscopic rotator cuff repairs by the same operator from March 2017 to July 2022 were retrospectively analyzed.The patients were divided into opioid group(62 patients)and control group(28 patients)according to whether they used opioid analgesics within 48 hours after surgery.The control group consisted of patients who did not use analgesics or who had good analgesic effects with conventional analgesic regimens(non-steroidal anti-inflammatory drugs or non-opioid central analgesics)after surgery,and the opioid group consisted of patients who required opioid analgesics as assessed by the surgeon or who need opioid analgesics because of inefficacy of conventional analgesic regimens.The following factors were selected as independent variables:gender,age(whether≥65 years old),duration of disease(whether≥4 weeks),body mass index(BMI)(whether≥25),occupation(whether employed),with or without a history of smoking and alcohol consumption,hypertension,diabetes,heart disease,and trauma,duration of surgery(whether≤180 min),number of torn tendons(whether≥2),number of screws(whether≥2),large nodular osteophyte,and whether there was moderate-to-severe impingement.Single factor analysis was used to screen the factors influencing the need for opioid analgesics within 48 hours after arthroscopic rotator cuff repair.Results The results of univariate analysis showed that among the above independent variables,only the number of torn tendons≥2 was the factor affecting the need for opioid analgesics within 48 hours after arthroscopic rotator cuff repair(OR = 5.263,P = 0.007).Conclusions Patients with rotator cuff tears with≥2 tendons had more severe pain within 48 hours after rotator cuff repair,requiring opioid analgesics.Focus should be placed on postoperative pain in such patients,and a diverse analgesic regimen should be used early.
8.One case of rhabdomyosarcoma with acute leukemia as the first symptom.
Xiupeng YE ; Shen BAO ; Ying GUO ; Yuping WEI ; Jianhua DING ; Jie BAI ; Fang LI ; Liyuan JIN
Chinese Journal of Hematology 2015;36(5):444-444